What Pharma Can Do About Brexit: Views From The C-Suite
Executive Summary
London-based pharma consultancy Novasecta systematically researched the implications of the Brexit vote over the three-month period since the UK referendum vote in late June. The firm shares insights from its conversations with pharma company execs, and offers advice on managing in these uncertain times.
You may also be interested in...
Brexit: What Can The Life Sciences Industry Do About It?
With the UK seemingly heading towards an exit from the European Union in just two and a half years’ time, restrictions on the free movement of people, products and finance will impact the life science sector as much as, if not more than, many others.
Brexit: UK Gov’t Says Retaining The EMA Cannot Be A “Line In The Sand” Matter
The European Medicines Agency is important to the UK but the government cannot say it will be a non-negotiable point in future talks regarding the country’s departure from the EU.
Brexit, Brexit Everywhere And Such A Lot To Think
For medtech manufacturers working in the EU market, the biggest regulatory changes for a generation are on the cusp of coming into force – at last. Or does this spell double trouble for UK manufacturers, who are rightly nervous about how Brexit will alter their business?